EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, New Horizon Health's enterprise value is HK$4,993 Mil.
New Horizon Health's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was HK$8 Mil. Therefore, New Horizon Health's EV-to-EBITDA for today is 663.94.
The historical rank and industry rank for New Horizon Health's EV-to-EBITDA or its related term are showing as below:
HKSE:06606'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -281.82 Med: -31.2 Max: 664.25
Current: 663.94
During the past 5 years, the highest EV-to-EBITDA of New Horizon Health was 664.25. The lowest was -281.82. And the median was -31.20.
HKSE:06606's EV-to-EBITDA is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 15.92
vs HKSE:06606: 663.94
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
New Horizon Health EV-to-EBITDA Historical Data
The historical data trend for New Horizon Health's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of New Horizon Health's EV-to-EBITDA
For the Medical Devices subindustry, New Horizon Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
New Horizon Health's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, New Horizon Health's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where New Horizon Health's EV-to-EBITDA falls into.
New Horizon Health's current Enterprise Value is HK$4,993 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. New Horizon Health's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was HK$8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
New Horizon Health (HKSE:06606) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
New Horizon Health's PE Ratio for today is calculated as:
New Horizon Health's share price for today is HK$14.14.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. New Horizon Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was HK$0.239.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of New Horizon Health's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
New Horizon Health (HKSE:06606) Business Description
New Horizon Health Ltd is engaged in early cancer screening and in-home testing in China. The company has an early detection and cancer screening-focused pipeline of five products and product candidates with an emphasis on colorectal cancer screening. The company focuses on cancer prevention and cure through screening and early detection. It generates maximum revenue from ColoClear and Pupu Tube products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:06606 has been successfully added to your 